Absence of HER2 overexpression in metastatic malignant melanoma

Journal of Surgical Oncology

Volumn 84, Issue 2, 2003, Pages 82-88

  Inman, J Lucas ^a   Kute, Tim ^a   White, Wain ^a   Pettenati, Mark ^a   Levine, Edward A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

HER2; Herceptin ; Melanoma; Metastasis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ONCOPROTEIN; PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; DIAGNOSTIC TEST; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; ONCOGENE NEU; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

BREAST NEOPLASMS; FEMALE; FLOW CYTOMETRY; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MELANOMA; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 0141927463     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.10297     Document Type: Article

References (26)

1. Levine EA, Holzmayer TA, Roninson IB, et al.: MDR-1 expression in metastatic malignant melanoma. J Surg Res 1993;54:621-624.
2. Atkins MB, Lotze MT, Dutcher JP, et al.: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-2116.
3. Clark WH, From L, Bernadino EA, et al.: The histogenesis and biological behavior of primary human malignant melanoma of the skin. Cancer Res 1992;29:705-726.
4. Gamel JW, George SL, Staley WE, et al.: Skin melanoma: Cured fraction and survival time as functions of thickness, site, histologic type, age, and sex. Cancer 1993;72:1219-1223.
5. Cristofolini M, Boi S, Girlando S, et al.: p53 protein expression in nevi and melanomas. Arch Dermatol 1993;129:739-743.
6. Lassam NJ, From L, Kahn HJ: Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 1993;53:2235-2238.
7. Gelsleichter L, Gown AM, Zarbo RJ, et al.: p53 and mdm-2 expression in malignant melanoma: An immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors. Mod Pathol 1995;8:530-535.
8. Slamon DJ, Clark GM, Wong SG, et al.: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
9. Slamon DJ, Godolphin W, Jones LA, et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
10. Paik S, Hazan R, Fisher ER, et al.: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990;8:103-112.
11. Winstanley J, Cooke T, Murray GD, et al.: The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 1991;63:447-450.
12. Toikkanen S, Helin H, Isola J, et al.: Prognostic significance of HER-2 oncoprotein expression in breast cancer: A 30-year follow-up. J Clin Oncol 1992;10:1044-1048.
13. Press MF, Pike MC, Chazin VR, et al.: Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960-4970.
14. Seshadri R, Firgaira FA, Horsfall DJ, et al.: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993;11:1936-1942.
15. Ravdin PM, Chamness GC: The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers - A review. Gene 1995;159:19-27.
16. Baselga J, Tripathy D, Mendelsohn J, et al.: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-744.
17. Cobleigh MA, Vogel CL, Tripathy D, et al.: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648.
18. Burstein HJ, Kuter I, Campos SM, et al.: Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19:2722-2730.
19. Seidman AD, Fornier MN, Esteva FJ, et al.: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587-2595.
20. Slamon DJ, Leyland-Jones B, Shak S, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
21. Bodey B, Bodey B, Jr., Groger AM, et al.: Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. Anticancer Res 1997;17:1319-1330.
22. Persons DL, Arber DA, Sosman JA, et al.: Amplification and overexpression of HER-2/neu are uncommon in advanced stage melanoma. Anticancer Res 2000;20:1965-1968.
23. Mayfield S, Vaughn JP, Kute TE: DNA strand breaks and cell cycle perturbation in Herceptin-treated breast cancer cell lines. Breast Cancer Res Treat 2001;70:123-129.
24. Easty DJ, Herlyn M, Bennett DL: Abnormal protein tyrosine kinase gene expression during melanoma progression and metastases. Int J Cancer 1995;60:129-136.
25. Chenevix-Trench G, Martin NG, Ellem KAO: Gene expression in melanoma cell lines and cultured melanocytes: Correlation between levels of c-src-1, c-myc, and p53. Oncogene 1990;5:1187-1193.
26. Fink-Puches R, Pilarski R, Schmidbauer U, et al.: No evidence for c-erb-B2 overexpression in cutaneous melanoma. Anticancer Res 2001;213:2793-2796.